Sino Biopharmaceutical Gains Approval for Cancer Drug

Sino Biopharmaceutical (HK:1177) has released an update.

Sino Biopharmaceutical has announced that its Eribulin Mesilate Injection has been approved by China’s National Medical Products Administration for treating advanced breast cancer. This approval marks one of the first three such injections sanctioned in China, highlighting the company’s strong R&D capabilities. With several promising drugs in the pipeline, Sino Biopharmaceutical is positioning itself as a leader in breast cancer treatment innovation.

For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.